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116E rotavirus vaccine development: a successful alliance
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In The Lancet, Nita Bhandari and colleagues’ study1 about the efficacy of the new 116E 
rotavirus vaccine in Indian infants offers an opportunity to address the substantial lag in 
translation of scientific progress for the benefit of the world’s most vulnerable population. 
Vaccination is considered to be second only to access to potable water in its potential cost-
effectiveness as a health-care strategy for improving child health. Most childhood deaths 
from vaccine-preventable diseases, such as Haemophilus influenzae type b (Hib), 
Streptococcus pneumoniae, and rotavirus, happen in low-income countries.2 However, 
introduction of lifesaving vaccines, such as Hib conjugate vaccine, into national 
immunisation programmes in low-income countries has lagged by as much as 20 years 
behind implementation in high-income settings.3 Of the many factors responsible, 
constraints around vaccine affordability and supply are key.
In the past decade, progress has been made in reducing the delay in the introduction of new 
childhood vaccines (eg, those against pneumococcus and rotavirus) into immunisation 
programmes between developed and developing countries. This progress is largely 
attributable to international donor funding coordinated under the auspices of the GAVI 
Alliance, which among other things provides cofinancing for vaccine procurement at 
discounted prices negotiated with manufacturers for countries that meet an income threshold 
for eligibility (presently a gross national income per person of =US$1550). However, the 
sustainability of the GAVI process, in which countries are expected to take over ownership 
of funding for vaccine procurement once their gross national income per person exceeds 
GAVI’s eligibility threshold, remains a concern. One way to address this challenge is to 
explore approaches to development of low-cost, safe, and effective vaccines that are 
affordable for low-income countries.
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Within this framework, the development of 116E rotavirus vaccine provides a model of a 
successful tripartite alliance between donors, governmental institutions, and a willing private 
sector, to ensure that vaccines are developed at affordable prices. Clinical development of 
the 116E vaccine was undertaken by an emerging Indian vaccine manufacturer—Bharat 
Biotech—with full partnership and partial financial support from the Department of 
Biotechnology of the Indian Government, and with technical and financial support from a 
consortium of international partners and donors. In lieu of public sector support to offset 
some of the research and development costs, the manufacturer has committed to making the 
vaccine available to the public sector at less than $1 per dose for a three-dose series. This 
regime is in comparison to the discounted cost, $2·50 per dose for a two-dose series and 
$3·50 per dose for a three-dose series, of two other licensed rotavirus vaccines that GAVI 
pays for countries that procure vaccine through UNICEF.4 Beneficiary low-income countries 
contribute $0·40 in co-financing for a full series of either vaccine.5
In Bhandari and colleagues’ study,1 which included more than 6500 infants aged 6–7 weeks 
in urban and rural settings, overall efficacy of the 116E vaccine against severe rotavirus 
gastroenteritis was 53·6% (95% CI 35·0–66·9). Efficacy during the first year of life was 
56·4% (36·6–70·1), which is similar to that of the two other licensed rotavirus vaccines in 
developing country settings: 50% (19–68) in Malawi for the monovalent rotavirus vaccine, 
and 46% (–1 to 72) in Bangladesh and 64% (40–79) in low-income African countries for the 
pentavalent rotavirus vaccine.6–8 The similar efficacy of 116E against severe rotavirus 
gastroenteritis caused by non-vaccine-type strains in post-hoc analysis is particularly 
reassuring in view of some concern that the unusual G9P[11] rotavirus strain in the 116E 
vaccine might protect less well against non-vaccine-type strains that cause most cases of 
severe disease in children in India and globally.9 Similar heterotypic protection has also been 
reported with the monovalent human-derived G1P[8] vaccine, and after natural rotavirus 
infection.10,11
Although a vaccine efficacy of 50–60% seems to be modest, on the basis of the tremendous 
health burden of severe rotavirus gastroenteritis in India and other low-income countries, 
even a vaccine with modest efficacy will have substantial public health benefit. Reassuringly, 
116E vaccine was not linked with intussusception—an adverse event that has been 
associated with other rotavirus vaccines in some settings. However, Bhandari and 
colleagues’ trial was inadequately powered to detect a low risk of adverse events, and 
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postmarketing efforts to monitor intussusception should continue. Furthermore, any risks 
identified should be weighed against the large anticipated benefits from vaccination.12
The successful testing and impending licensure of the 116E vaccine, followed by its 
potential inclusion into the national immunisation programme of India, represents a major 
milestone in global efforts to reduce rotavirus-associated morbidity and mortality in India, 
the country which singularly accounts for about a fifth of global deaths from rotavirus.13 
Should the vaccine be prequalified by WHO, it will provide an additional affordable product 
to meet the large demand of the global market. The public–private sector partnership to 
develop and test the vaccine (somewhat similar to the approach used to develop a new 
meningitis vaccine, MenAfriVac, that is already realising a huge public health effect in 
Africa) provides an alternative model of risk and cost sharing to develop life-saving vaccines 
that are effective, safe, and affordable for use in low-income countries.
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